Latest

Clinical Trials in the UK / NCT06465810

Recruiting Observational

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810 · tracked via the Priya Life Science UK tracker

Sponsor

AstraZeneca

Phase

Observational

Started

2024-06-25

Last updated

—

Condition(s) studied

Transthyretin AmyloidosisATTR-CMATTRv-PNATTR

More AstraZeneca trials in the UK

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Enrolling by invitation

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors Recruiting

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer Active, not recruiting

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus Active, not recruiting

Other trials for the same condition

Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06465810 on ClinicalTrials.gov ↗ ← All trials in the UK